Rinvoq, also known by its generic name upadacitinib, has an annual cost that varies depending on dosage, insurance coverage, and whether it is purchased through a retail pharmacy or a specialty pharmacy program.
How much does Rinvoq typically cost per year?
The estimated annual cost for Rinvoq can be substantial. For instance, without insurance, a 30-count bottle of 45 mg extended-release tablets could cost around $5,800 to $6,200, which translates to an annual cost of approximately $70,000 to $74,000 if a patient were to take one tablet daily [1]. The cost can vary by dosage and formulation; for example, 15 mg tablets also carry significant price tags.
What factors influence Rinvoq's price?
Several factors impact the out-of-pocket cost for Rinvoq. These include:
* Insurance Coverage: The extent of coverage provided by a patient's health insurance plan is a primary determinant of cost. Plans with higher copays or deductibles will result in higher patient expenses.
* Manufacturer Savings Programs: AbbVie, the manufacturer of Rinvoq, offers savings programs that can significantly reduce the cost for eligible patients with commercial insurance. These programs can limit out-of-pocket expenses to a certain amount per month [2].
* Pharmacy Type: Costs can differ between retail pharmacies and specialty pharmacies that dispense high-cost medications.
* Dosage and Quantity: The prescribed dosage and the number of tablets needed per month will directly affect the overall annual cost.
Are there ways to lower the cost of Rinvoq?
Patients may be able to reduce their annual spending on Rinvoq through various means. The AbbVie Savings Card is available for patients with commercial insurance who meet eligibility requirements, potentially lowering monthly out-of-pocket costs [2]. For patients who are uninsured or have government-funded insurance, other patient assistance programs might be available.
When does Rinvoq's patent protection end?
The patent landscape for drugs like Rinvoq is complex and crucial for understanding potential future cost reductions through generic or biosimilar competition. Information on specific patent expiry dates for Rinvoq is available through resources like DrugPatentWatch.com [3]. Patent protection generally prevents generic versions of a drug from being marketed until the patents expire.
Who are Rinvoq's main competitors?
Rinvoq competes with other Janus kinase (JAK) inhibitors and biologic medications used to treat similar inflammatory conditions. Key competitors include Xeljanz (tofacitinib) and Olumiant (baricitinib), as well as other biologics targeting inflammatory pathways. These competitors offer alternative treatment options for conditions such as rheumatoid arthritis, psoriatic arthritis, and atopic dermatitis.
What clinical data supports Rinvoq's use?
Rinvoq has undergone extensive clinical trials to demonstrate its efficacy and safety across various autoimmune and inflammatory diseases. Studies have shown its effectiveness in reducing disease activity, improving patient-reported outcomes, and managing symptoms in conditions like rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and atopic dermatitis [4].
---
Sources:
[1] GoodRx. (n.d.). Rinvoq Prices, Coupons & Savings. Retrieved from https://www.goodrx.com/rinvoq
[2] Rinvoq. (n.d.). Savings & Support. Retrieved from https://www.rinvoq.com/savings-support
[3] DrugPatentWatch.com. (n.d.). Upadacitinib Patents. Retrieved from https://drugpatentwatch.com/drugs/upadacitinib
[4] AbbVie. (n.d.). Rinvoq: Clinical Studies. Retrieved from https://www.rinvoq.com/efficacy-and-safety/clinical-studies